Table 2.

Cerivcogenital HPV prevalence by genotype group and relative risk by vaccination status

		Unvaccinated			Vaccinated			Relative risk
Age	Genotypes	N	% +	S.E.	N	% +	S.E.	RR	95 % CI
	All	244	17.5	2.7	233	20.1	3.5	1.1	0.7–1.8
14–17	Group 1	244	12.4	2.7	233	11.2	2.9	0.9	0.5–1.8
	6, 11, 16, 18	244	4.5	1.7	233	1.0	0.5	0.2	0.1–0.8
	All	448	57.7	3.4	241	56.9	3.5	1.0	0.8–1.2
18–24	Group 1	448	38.8	3.5	241	30.9	3.5	0.8	0.6–1.1
	6, 11, 16, 18	448	16.6	2.5	241	2.5	0.7	0.2	0.1–0.3

Prevalence is by all, oncogenic (Group 1 genotypes), and vaccine genotypes for women ages 14–17 and 18–24 in 2009–12. Here, %+ denotes the weighted cervicogenital HPV prevalence of the listed genotypes among the N people in the population. Bold relative risks intervals do not contain 1